Exelixis | Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 356.58M 26.56M 2025-09
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Akebia Therapeutics USD 133.38M 14.66M 2025-09
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Bayer EUR 28.96B 825M 2025-09
BioMarin Pharmaceutical USD 798.44M 114.19M 2025-09
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Cytokinetics USD 142.14M 11.08M 2025-09
Eisai JPY 387.67B 9.42B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Esperion Therapeutics USD 359.03M 60.24M 2025-09
Exelixis USD 405.64M 31.86M 2025-12
Genmab DKK 629M 127M 2025-06
Glaxosmithkline GBP 28.68B 8.3B 2025-09
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 903.46M 6.22M 2025-09
MacroGenics USD 44.47M 5.47M 2025-09
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 32B 286M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 28.35B 9.32B 2025-12
Takeda JPY 2.61T 470.53B 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Xencor USD 86.48M 9.6M 2025-09


Exelixis Passività Correnti - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.